JNJ-63576253   Click here for help

GtoPdb Ligand ID: 12709

Synonyms: compound 5 [PMID: 33470111] | JNJ63576253 | TRC-253 | TRC253
Compound class: Synthetic organic
Comment: JNJ-63576253 is an androgen receptor (AR) antagonist with activity at wild type AR and the enzalutamide/apalutamide resistance mutant ARF877L [1-2]. It was designed for potential to treat castration-resistant prostate cancer.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 125.41
Molecular weight 502.51
XLogP 1.65
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CC2(C1)C(=O)N(C3=CN=C(C#N)C(=C3)C(F)(F)F)C(=S)N2C4=CC=C(N=C4)OC5CCNCC5
Isomeric SMILES N#CC1=C(C=C(N2C(C3(CCC3)N(C4=CN=C(OC5CCNCC5)C=C4)C2=S)=O)C=N1)C(F)(F)F
InChI InChI=1S/C23H21F3N6O2S/c24-23(25,26)17-10-15(13-29-18(17)11-27)31-20(33)22(6-1-7-22)32(21(31)35)14-2-3-19(30-12-14)34-16-4-8-28-9-5-16/h2-3,10,12-13,16,28H,1,4-9H2
InChI Key OUEHJEYKNYQVRC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
As TRC253, this AR antagonist was progressed to clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02987829 Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Phase 1/Phase 2 Interventional Tracon Pharmaceuticals Inc.